Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer.
combined chemotherapies
targeted liposomes
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jul 2021
26 Jul 2021
Historique:
received:
30
06
2021
revised:
23
07
2021
accepted:
24
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies are currently the main treatment options, but their clinical efficacies are limited and patients usually suffer from severe side effects. The goal of this study was to develop and evaluate targeted liposomes-delivered combined chemotherapies to treat TNBCs. Specifically, the IC
Identifiants
pubmed: 34359650
pii: cancers13153749
doi: 10.3390/cancers13153749
pmc: PMC8345094
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA238273
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242917
Pays : United States
Organisme : NIH HHS
ID : 1R01CA238273-01A1; 1R01CA242917-01A1
Pays : United States
Références
Am J Cancer Res. 2016 Aug 01;6(8):1609-23
pubmed: 27648353
Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):489-495
pubmed: 33729079
BMC Cancer. 2018 Aug 13;18(1):813
pubmed: 30103710
Front Immunol. 2018 Feb 05;9:155
pubmed: 29459867
Sci Rep. 2019 Feb 25;9(1):2723
pubmed: 30804365
Jpn J Cancer Res. 1998 Apr;89(4):352-4
pubmed: 9617338
J Control Release. 2005 Nov 28;108(2-3):484-95
pubmed: 16181701
Int J Mol Sci. 2019 Dec 03;20(23):
pubmed: 31816851
Cancer Chemother Pharmacol. 2016 Jul;78(1):13-26
pubmed: 27118574
Lancet Oncol. 2013 Jul;14(8):697-710
pubmed: 23746666
Viruses. 2020 Jun 20;12(6):
pubmed: 32575696
Sci Rep. 2019 Oct 22;9(1):15120
pubmed: 31641141
Cells. 2019 Aug 22;8(9):
pubmed: 31443516
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
Iran J Pharm Res. 2016 Winter;15(Suppl):3-17
pubmed: 28228799
Int J Mol Cell Med. 2018 Fall;7(4):234-240
pubmed: 31516883
Pharmacol Ther. 2019 Jul;199:30-57
pubmed: 30825473
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
pubmed: 11597399
Biotechnol J. 2020 Jan;15(1):e1900163
pubmed: 31595685
Int J Pharm. 2007 Jun 29;338(1-2):317-26
pubmed: 17368984
Signal Transduct Target Ther. 2017;2:
pubmed: 28435746
Front Pharmacol. 2017 Oct 06;8:595
pubmed: 29056908
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
Results Pharma Sci. 2011 Sep 03;1(1):49-56
pubmed: 25755981
J Oncol. 2009;2009:526963
pubmed: 19390622
Pharmaceuticals (Basel). 2021 May 02;14(5):
pubmed: 34063284
Expert Opin Biol Ther. 2003 Apr;3(2):377-84
pubmed: 12662150
N Engl J Med. 2007 Nov 15;357(20):2040-8
pubmed: 18003960
Cancer Res. 1984 Aug;44(8):3442-7
pubmed: 6331647
ACS Synth Biol. 2020 Feb 21;9(2):343-355
pubmed: 31891494
Am J Physiol. 1999 Dec;277(6):H2392-9
pubmed: 10600860
Pharmaceutics. 2020 Nov 11;12(11):
pubmed: 33187322
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Int J Oncol. 2018 Sep;53(3):1105-1117
pubmed: 29956746
Stem Cells. 2013 Feb;31(2):248-58
pubmed: 23169551
J Cell Physiol. 2019 Nov;234(11):20769-20778
pubmed: 31001890
Biomed Pharmacother. 2014 May;68(4):429-38
pubmed: 24721327
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
pubmed: 15328174
Int J Pharm. 2019 Apr 5;560:57-64
pubmed: 30699364
Expert Opin Drug Deliv. 2005 Mar;2(2):237-54
pubmed: 16296751
Biomater Res. 2019 Mar 12;23:8
pubmed: 30915230
PLoS One. 2012;7(7):e41410
pubmed: 22844475
Cancer Manag Res. 2020 Jan 30;12:703-717
pubmed: 32099467
Cell Death Dis. 2018 Jan 16;9(2):19
pubmed: 29339815
Theranostics. 2019 Oct 22;9(26):8362-8376
pubmed: 31754402
Cancer Gene Ther. 2020 Jul 20;:
pubmed: 32684623
Onco Targets Ther. 2019 Sep 20;12:7749-7756
pubmed: 31571924
J Control Release. 2012 Jan 30;157(2):279-86
pubmed: 21871507
Mol Cancer Ther. 2014 May;13(5):1356-68
pubmed: 24634415
Ann Oncol. 2003 Sep;14(9):1346-63
pubmed: 12954573
Mol Biotechnol. 2010 Feb;44(2):152-67
pubmed: 19950006
Int J Pharm. 2020 Feb 25;576:118999
pubmed: 31893541
Lancet Respir Med. 2015 Sep;3(9):684-691
pubmed: 26149841
Clin Cancer Res. 2018 Oct 15;24(20):5098-5111
pubmed: 30068707
Drug Resist Updat. 2016 Jan;24:13-22
pubmed: 26830312
Langmuir. 2012 Mar 13;28(10):4729-36
pubmed: 22268611
Breast Cancer Res Treat. 2013 Feb;137(3):773-82
pubmed: 23288347
Br J Cancer. 2003 Oct 20;89(8):1545-51
pubmed: 14562030
Eur J Pharm Biopharm. 2019 Mar;136:203-212
pubmed: 30677497
Int J Nanomedicine. 2019 Dec 04;14:9547-9561
pubmed: 31824150
Transl Lung Cancer Res. 2014 Dec;3(6):395-6
pubmed: 25806331
Oncotarget. 2018 May 22;9(39):25545-25556
pubmed: 29876007
Gene Ther. 2017 Aug;24(8):441-452
pubmed: 28504657
J Lab Physicians. 2015 Jul-Dec;7(2):79-83
pubmed: 26417156
Breast. 2017 Aug;34 Suppl 1:S27-S30
pubmed: 28668293
Br J Cancer. 2017 May 9;116(10):1271-1278
pubmed: 28399112
Oncol Lett. 2019 Jan;17(1):3-10
pubmed: 30655732
Clin Cancer Res. 2001 Aug;7(8):2285-91
pubmed: 11489803
PLoS One. 2012;7(10):e46614
pubmed: 23071597
Gynecol Oncol. 2017 Nov;147(2):283-290
pubmed: 28802766
PLoS One. 2013 Jun 11;8(6):e66128
pubmed: 23776619
Cancer Treat Rev. 2018 Feb;63:48-60
pubmed: 29223828
Semin Oncol. 2004 Dec;31(6 Suppl 18):47-51
pubmed: 15726523
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Eng Life Sci. 2020 Oct 07;21(1-2):37-44
pubmed: 33531889
Int J Pharm. 2019 Oct 5;569:118605
pubmed: 31400433
Cancer Res. 1995 Jun 1;55(11):2366-72
pubmed: 7757988